Embecta (EMBC) Stock Forecast, Price Target & Predictions
EMBC Stock Forecast
Embecta stock forecast is as follows: an average price target of $12.00 (represents a -17.47% downside from EMBC’s last price of $14.54) and a rating consensus of 'Sell', based on 1 wall street analysts offering a 1-year stock forecast.
EMBC Price Target
The average price target for Embecta (EMBC) is $12.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $12.00. This represents a potential -17.47% downside from EMBC's last price of $14.54.
EMBC Analyst Ratings
According to 1 Wall Street analysts, Embecta's rating consensus is 'Sell'. The analyst rating breakdown for EMBC stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 0 'Hold' (0.00%), 1 'Sell' (100.00%), and 0 'Strong Sell' (0.00%).
Embecta Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 15, 2024 | Kallum Titchmarsh | Morgan Stanley | $12.00 | $13.17 | -8.88% | -17.47% |
| Aug 16, 2022 | - | Morgan Stanley | $36.00 | $33.42 | 7.72% | 147.59% |
The latest Embecta stock forecast, released on Jul 15, 2024 by Kallum Titchmarsh from Morgan Stanley, set a price target of $12.00, which represents a -8.88% decrease from the stock price at the time of the forecast ($13.17), and a -17.47% decrease from EMBC last price ($14.54).
Embecta Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $12.00 |
| Last Closing Price | $14.54 | $14.54 | $14.54 |
| Upside/Downside | -100.00% | -100.00% | -17.47% |
In the current month, the average price target of Embecta stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Embecta's last price of $14.54. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 15, 2024 | Morgan Stanley | Underweight | Underweight | Hold |
| May 15, 2023 | Morgan Stanley | Underweight | Underweight | Hold |
| Jun 21, 2022 | Bank of America Securities | - | Underperform | Initialise |
Embecta's last stock rating was published by Morgan Stanley on Jul 15, 2024. The company gave EMBC a "Underweight" rating, the same as its previous rate.
Embecta Financial Forecast
Embecta Revenue Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $277.30M | $281.90M | - | $277.10M | $275.70M | $274.60M | $291.10M |
| Avg Forecast | $283.29M | $280.65M | $277.44M | $272.03M | $281.87M | $279.17M | $281.10M | $277.25M | $276.97M | $267.44M | $264.70M | $264.92M | $271.55M | $275.07M | $262.88M | $262.90M | $261.01M | $276.86M |
| High Forecast | $283.29M | $280.65M | $277.44M | $272.03M | $281.87M | $279.17M | $281.10M | $277.25M | $278.09M | $267.44M | $264.70M | $264.92M | $272.73M | $275.07M | $262.88M | $262.90M | $261.01M | $276.86M |
| Low Forecast | $283.29M | $280.65M | $277.44M | $272.03M | $281.87M | $279.17M | $281.10M | $277.25M | $275.84M | $267.44M | $264.70M | $264.92M | $270.38M | $275.07M | $262.88M | $262.90M | $261.01M | $276.86M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.05% | 1.04% | - | 1.05% | 1.05% | 1.05% | 1.05% |
Embecta's average Quarter revenue forecast for Mar 24 based on 1 analysts is $264.70M, with a low forecast of $264.70M, and a high forecast of $264.70M. EMBC's average Quarter revenue forecast represents a -4.55% decrease compared to the company's last Quarter revenue of $277.30M (Dec 23).
Embecta EBITDA Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $45.50M | $44.40M | - | $59.30M | $88.90M | $53.20M | $102.20M |
| Avg Forecast | $112.88M | $111.82M | $110.55M | $108.39M | $112.31M | $111.24M | $112.00M | $110.47M | $110.36M | $106.56M | $105.47M | $105.56M | $108.20M | $109.60M | $104.75M | $104.75M | $104.00M | $110.32M |
| High Forecast | $112.88M | $111.82M | $110.55M | $108.39M | $112.31M | $111.24M | $112.00M | $110.47M | $110.81M | $106.56M | $105.47M | $105.56M | $108.67M | $109.60M | $104.75M | $104.75M | $104.00M | $110.32M |
| Low Forecast | $112.88M | $111.82M | $110.55M | $108.39M | $112.31M | $111.24M | $112.00M | $110.47M | $109.91M | $106.56M | $105.47M | $105.56M | $107.73M | $109.60M | $104.75M | $104.75M | $104.00M | $110.32M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.43% | 0.41% | - | 0.57% | 0.85% | 0.51% | 0.93% |
1 analysts predict EMBC's average Quarter EBITDA for Mar 24 to be $105.47M, with a high of $105.47M and a low of $105.47M. This is 131.80% upper than Embecta's previous annual EBITDA (Dec 23) of $45.50M.
Embecta Net Income Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $20.10M | $6.00M | - | $14.00M | $35.20M | $-17.20M | $62.40M |
| Avg Forecast | $31.55M | $31.18M | $28.85M | $27.58M | $31.52M | $34.01M | $33.43M | $32.51M | $20.94M | $26.84M | $23.14M | $26.32M | $22.99M | $26.61M | $27.96M | $29.50M | $34.51M | $50.32M |
| High Forecast | $31.55M | $31.18M | $28.85M | $27.58M | $31.52M | $34.01M | $33.43M | $32.51M | $30.88M | $26.84M | $23.14M | $27.49M | $27.02M | $26.61M | $27.96M | $29.50M | $34.51M | $50.32M |
| Low Forecast | $31.55M | $31.18M | $28.85M | $27.58M | $31.52M | $34.01M | $33.43M | $32.51M | $15.70M | $26.84M | $23.14M | $25.15M | $21.27M | $26.61M | $27.96M | $29.50M | $34.51M | $50.32M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.76% | 0.26% | - | 0.50% | 1.19% | -0.50% | 1.24% |
Embecta's average Quarter net income forecast for Mar 24 is $23.14M, with a range of $23.14M to $23.14M. EMBC's average Quarter net income forecast represents a 15.11% increase compared to the company's last Quarter net income of $20.10M (Dec 23).
Embecta SG&A Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $90.30M | $95.70M | - | $85.20M | $72.80M | $81.90M | $83.80M |
| Avg Forecast | $66.26M | $65.64M | $64.89M | $63.63M | $65.93M | $65.30M | $65.75M | $64.85M | $64.78M | $62.55M | $61.91M | $61.96M | $63.51M | $64.34M | $61.49M | $61.49M | $61.05M | $64.76M |
| High Forecast | $66.26M | $65.64M | $64.89M | $63.63M | $65.93M | $65.30M | $65.75M | $64.85M | $65.04M | $62.55M | $61.91M | $61.96M | $63.79M | $64.34M | $61.49M | $61.49M | $61.05M | $64.76M |
| Low Forecast | $66.26M | $65.64M | $64.89M | $63.63M | $65.93M | $65.30M | $65.75M | $64.85M | $64.52M | $62.55M | $61.91M | $61.96M | $63.24M | $64.34M | $61.49M | $61.49M | $61.05M | $64.76M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.46% | 1.51% | - | 1.39% | 1.18% | 1.34% | 1.29% |
Embecta's average Quarter SG&A projection for Mar 24 is $61.91M, based on 1 Wall Street analysts, with a range of $61.91M to $61.91M. The forecast indicates a -31.44% fall compared to EMBC last annual SG&A of $90.30M (Dec 23).
Embecta EPS Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $0.35 | $0.10 | - | $0.24 | $0.62 | $-0.30 | $1.08 |
| Avg Forecast | $0.55 | $0.54 | $0.50 | $0.48 | $0.55 | $0.59 | $0.58 | $0.56 | $0.36 | $0.46 | $0.40 | $0.46 | $0.40 | $0.46 | $0.48 | $0.51 | $0.60 | $0.87 |
| High Forecast | $0.55 | $0.54 | $0.50 | $0.48 | $0.55 | $0.59 | $0.58 | $0.56 | $0.53 | $0.46 | $0.40 | $0.48 | $0.47 | $0.46 | $0.48 | $0.51 | $0.60 | $0.87 |
| Low Forecast | $0.55 | $0.54 | $0.50 | $0.48 | $0.55 | $0.59 | $0.58 | $0.56 | $0.27 | $0.46 | $0.40 | $0.43 | $0.37 | $0.46 | $0.48 | $0.51 | $0.60 | $0.87 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.77% | 0.25% | - | 0.50% | 1.22% | -0.50% | 1.24% |
According to 1 Wall Street analysts, Embecta's projected average Quarter EPS for Mar 24 is $0.40, with a low estimate of $0.40 and a high estimate of $0.40. This represents a 14.29% increase compared to EMBC previous annual EPS of $0.35 (Dec 23).
Embecta Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| AKYA | Akoya Biosciences | $2.62 | $7.90 | 201.53% | Buy |
| COO | Cooper Companies | $104.86 | $298.00 | 184.19% | Buy |
| ANGO | AngioDynamics | $6.74 | $15.00 | 122.55% | Buy |
| BAX | Baxter | $35.80 | $60.38 | 68.66% | Hold |
| ATRC | AtriCure | $33.66 | $49.57 | 47.27% | Buy |
| TFX | Teleflex | $207.33 | $304.82 | 47.02% | Buy |
| HAE | Haemonetics | $73.53 | $104.33 | 41.89% | Buy |
| WST | West Pharmaceutical Services | $314.77 | $345.33 | 9.71% | Buy |
| NVST | Envista | $21.28 | $23.13 | 8.69% | Hold |
| ALC | Alcon | $92.17 | $93.89 | 1.87% | Buy |
| MMSI | Merit Medical Systems | $99.08 | $100.78 | 1.72% | Buy |
| ICUI | ICU Medical | $172.00 | $172.00 | - | Buy |
| RMD | ResMed | $243.61 | $219.13 | -10.05% | Hold |
| EMBC | Embecta | $14.54 | $12.00 | -17.47% | Sell |
| ATR | AptarGroup | $168.26 | $138.00 | -17.98% | Buy |
EMBC Forecast FAQ
Is Embecta a good buy?
No, according to 1 Wall Street analysts, Embecta (EMBC) is considered a 'Sell'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of EMBC's total ratings.
What is EMBC's price target?
Embecta (EMBC) average price target is $12 with a range of $12 to $12, implying a -17.47% from its last price of $14.54. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Embecta stock go up soon?
According to Wall Street analysts' prediction for EMBC stock, the company can go down by -17.47% (from the last price of $14.54 to the average price target of $12), down by -17.47% based on the highest stock price target, and down by -17.47% based on the lowest stock price target.
Can Embecta stock reach $20?
EMBC's average twelve months analyst stock price target of $12 does not support the claim that Embecta can reach $20 in the near future.
What are Embecta's analysts' financial forecasts?
Embecta's analysts financial forecasts for the fiscal year (Sep 2025) are as follows: average revenue is $1.12B (high $1.12B, low $1.12B), average EBITDA is $446.02M (high $446.02M, low $446.02M), average net income is $131.47M (high $131.47M, low $131.47M), average SG&A $261.82M (high $261.82M, low $261.82M), and average EPS is $2.27 (high $2.27, low $2.27). EMBC's analysts financial forecasts for the fiscal year (Sep 2026) are as follows: average revenue is $1.11B (high $1.11B, low $1.11B), average EBITDA is $443.64M (high $443.64M, low $443.64M), average net income is $119.17M (high $119.17M, low $119.17M), average SG&A $260.43M (high $260.43M, low $260.43M), and average EPS is $2.06 (high $2.06, low $2.06).
Did the EMBC's actual financial results beat the analysts' financial forecasts?
Based on Embecta's last annual report (Sep 2023), the company's revenue was $1.12B, beating the average analysts forecast of $1.07B by 4.51%. Apple's EBITDA was $247.8M, missing the average prediction of $427.3M by -42.01%. The company's net income was $70.4M, missing the average estimation of $107.06M by -34.24%. Apple's SG&A was $341.3M, beating the average forecast of $250.83M by 36.07%. Lastly, the company's EPS was $1.22, missing the average prediction of $1.85 by -34.08%. In terms of the last quarterly report (Dec 2023), Embecta's revenue was $277.3M, beating the average analysts' forecast of $264.92M by 4.67%. The company's EBITDA was $45.5M, missing the average prediction of $105.56M by -56.90%. Embecta's net income was $20.1M, missing the average estimation of $26.32M by -23.63%. The company's SG&A was $90.3M, beating the average forecast of $61.96M by 45.73%. Lastly, the company's EPS was $0.35, missing the average prediction of $0.455 by -23.08%